Trial Profile
Phase II Open, Non-Randomized Trial Assessing Pain Efficacy With Radium-223 in Symptomatic Metastatic Castration-Resistant Prostate Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Apr 2023
Price :
$35
*
At a glance
- Drugs Radium 223 chloride (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- 03 Feb 2022 Status changed from active, no longer recruiting to completed.
- 09 Aug 2021 Planned End Date changed from 1 Oct 2021 to 1 Oct 2022.
- 09 Aug 2021 Planned primary completion date changed from 1 Oct 2021 to 1 Oct 2022.